Johnson & Johnson (JNJ)

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Ticker
JNJ
Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers - General
Market cap
$680.83B
52-week range
$193.55 - $290.25

Valuation

Share price
$282.55 (close of Nov 16, 2026)
P/E (TTM)
42.30x
Price to book
8.35x
Price to free cash flow
33.07x
Enterprise value
$708.26B
Book value per share
$33.84

Price performance

PeriodChange
1 day-1.12%
5 days+0.16%
1 month+10.56%
3 months+8.53%
6 months+24.63%
Year to date+36.53%
1 year+44.21%
3 years+88.24%
5 years+73.70%
10 years+142.82%
All time+23,083.59%

Short interest

As of
Oct 30, 2026
Short % of float
0.79%
Shares short
17.07M
Days to cover
2.41
Change since prior report
+1.80%
Source
FINRA consolidated short interest

Members of Congress who disclosed JNJ trades

Thomas Kean · Lloyd Doggett · Josh Gottheimer · Lisa McClain · Richard McCormick · Gilbert Ray Cisneros · Julie Johnson · Marjorie Taylor Greene · Jefferson Shreve · Alan Armstrong · Bruce Westerman · Jared Moskowitz

And 12 others

Super investors holding JNJ

Ken Griffin (Citadel) · Yacktman Asset Mgmt (Yacktman Asset Management LP) · Ray Dalio (Bridgewater Associates) · Mairs & Power (Mairs & Power Inc) · Tweedy Browne (Tweedy Browne Company LLC) · Prem Watsa (Fairfax Financial Holdings) · John Rogers (Ariel Investments LLC) · George Soros (Soros Fund Mgmt) · Robert Olstein (Olstein Capital Management) · Dodge & Cox (Dodge & Cox Funds) · David Katz (Matrix Asset Advisors Inc) · Thomas Russo (Gardner Russo & Quinn LLC)

And 1 other

Profitability and growth

Return on equity
32.87%
Return on invested capital
21.45%*
Return on assets
13.46%
Return on capital employed
23.13%*
Gross margin
67.88%
Net margin
28.46%
EBITDA margin
43.59%
Revenue growth
6.05%
Net income growth
90.56%
Free cash flow growth
-0.73%

* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.

Cash flow and balance sheet

Free cash flow yield (TTM)
3.02%
Current ratio
1.02x
Net debt to EBITDA
1.02x

Latest reported year

Period end
Dec 28, 2025
Fiscal year
2025
Revenue
$94.19B
Cost of revenue
$30.26B
Gross profit
$63.94B
EBITDA
$41.05B
Net income
$26.80B
Earnings per share
$11.13
Research and development
$14.66B
Interest expense
$971.00M
Shares outstanding
2.41B

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-28$94.19B$63.94B$26.80B$11.13
2024-12-29$88.82B$61.35B$14.07B$5.84
2023-12-31$85.16B$58.61B$35.15B$13.88
2023-01-01$79.99B$55.39B$17.94B$6.83
2022-01-02$78.74B$55.34B$20.88B$7.93
2021-01-03$82.58B$54.16B$14.71B$5.59
2019-12-29$82.06B$54.50B$15.12B$5.72
2018-12-30$81.58B$54.49B$15.30B$5.70
2017-12-31$76.45B$51.01B$1.30B$0.48
2017-01-01$71.89B$50.10B$16.54B$6.04

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-2867.88%28.46%32.87%21.45%*
2024-12-2969.07%15.84%19.68%13.71%*
2023-12-3168.82%41.28%51.11%14.37%*
2023-01-0169.25%22.43%23.36%14.30%*
2022-01-0270.28%26.52%28.20%16.53%*
2021-01-0365.58%17.82%23.25%14.97%*
2019-12-2966.42%18.42%25.42%17.51%*
2018-12-3066.79%18.75%25.60%18.07%*
2017-12-3166.72%1.70%2.16%9.82%*
2017-01-0169.69%23.01%23.49%17.70%*

* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.

Cash and debt by year

Period endCashDebt
2025-12-28$19.71B$39.44B
2024-12-29$24.11B$30.65B
2023-12-31$21.86B$25.88B
2023-01-01$12.89B$26.89B
2022-01-02$14.49B$29.98B
2021-01-03$25.18B$32.63B
2019-12-29$19.29B$26.49B
2018-12-30$19.69B$27.68B
2017-12-31$18.30B$30.68B
2017-01-01$41.91B$22.44B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-28$19.70B$1.35B
2024-12-29$19.84B$1.18B
2023-12-31$18.25B$1.16B
2023-01-01$17.18B$1.14B
2022-01-02$19.76B$1.14B
2021-01-03$20.19B$1.00B
2019-12-29$19.92B$977.00M
2018-12-30$18.53B$978.00M
2017-12-31$17.78B$962.00M
2017-01-01$15.54B$878.00M

Dividend history

Most recent payment
Aug 25, 2026
Paid in the last twelve months
$5.28
Payment dateDividend per share
2026-08-25$1.34
2026-05-26$1.34
2026-02-24$1.30
2025-11-25$1.30
2025-08-26$1.30
2025-05-27$1.30
2025-02-18$1.24
2024-11-26$1.24

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-10-13Sep 2026$2.53
2026-07-15Jun 2026$2.84
2026-04-14Mar 2026$2.67
2026-01-21Dec 2025$2.43
2025-10-14Sep 2025$2.77
2025-07-16Jun 2025$2.66
2025-04-15Mar 2025$2.57
2025-01-22Dec 2024$2.00

Filings and sources

Company website
jnj.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

AbbVie Inc. (ABBV) · Eli Lilly & Co (LLY) · Merck & Co., Inc. (MRK) · Novartis AG (NVS) · AstraZeneca plc (AZN) · Amgen Inc (AMGN) · Gilead Sciences, Inc. (GILD) · Pfizer Inc (PFE)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades